Cargando…

Discriminating Potential Genetic Markers for Complete Response and Non-Complete Response Patients to Neoadjuvant Chemotherapy with Locally Advanced Rectal Cancer

Background: Neoadjuvant chemoradiotherapy (nCRT) prior to surgery is considered standard therapy for locally advanced rectal cancer. Unfortunately, most patients with rectal cancer are resistant to radiotherapy. This might be a genetic cause. The role of certain rectal cancer-causing genes has not b...

Descripción completa

Detalles Bibliográficos
Autores principales: Bagaria, Jaya, Kim, Kyung-Ok, Bagyinszky, Eva, An, Seong Soo A., Baek, Jeong-Heum
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997875/
https://www.ncbi.nlm.nih.gov/pubmed/35409691
http://dx.doi.org/10.3390/ijerph19074008
_version_ 1784684807564820480
author Bagaria, Jaya
Kim, Kyung-Ok
Bagyinszky, Eva
An, Seong Soo A.
Baek, Jeong-Heum
author_facet Bagaria, Jaya
Kim, Kyung-Ok
Bagyinszky, Eva
An, Seong Soo A.
Baek, Jeong-Heum
author_sort Bagaria, Jaya
collection PubMed
description Background: Neoadjuvant chemoradiotherapy (nCRT) prior to surgery is considered standard therapy for locally advanced rectal cancer. Unfortunately, most patients with rectal cancer are resistant to radiotherapy. This might be a genetic cause. The role of certain rectal cancer-causing genes has not been completely elucidated. This study aims to investigate the genes responsible for locally advanced rectal cancer patients not reacting to radiotherapy. Methods: Whole exome sequencing of the DNA samples was performed on the samples. Bioinformatic analysis on the subjects was established. Individual genetic information was screened to identify differently expressed genes that more frequently appeared in non-complete response (NCR) compared to complete response (CR) patients after nCRT. All variations were verified by Sanger sequencing. Results: Genotyping information and pathway analyses of the samples indicated genes such as FLCN, CALML5, and ANTXR1 to be commonly mutated in CR group, whereas genes such as GALNTL14, CNKSR1, ACD, and CUL3 were more commonly mutated in the NCR group. Chi-square test revealed some significant variants (<0.05) such as rs3744124 (FLCN), rs28365986 (ANTXR1), rs10904516 (CALML5), rs3738952 (CUL3), rs13394 and rs2293013 (PIH1D1), rs2274531 (GPA33), rs4963048 (BRSK2), rs17883366 (IL3RA), rs2297575 (PSMD5), rs2288101 (GALNT14), and rs11954652 (DCTN4). Conclusion: Identifying an array of genes that separate NCRs from CRs would lead to finding genetic biomarkers for early detection of rectal cancer patients that are resistant to nCRT. A further investigation to validate the significance of genetic biomarkers to segregate NCRs from CRs should be performed with a larger CRC dataset. Protein expression levels, as well as transcriptomic analysis, would also help us understand the mechanism of how these genes could play a role in preventing radiation therapy to patients. This would be essential to prevent redundant radiation therapy.
format Online
Article
Text
id pubmed-8997875
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89978752022-04-12 Discriminating Potential Genetic Markers for Complete Response and Non-Complete Response Patients to Neoadjuvant Chemotherapy with Locally Advanced Rectal Cancer Bagaria, Jaya Kim, Kyung-Ok Bagyinszky, Eva An, Seong Soo A. Baek, Jeong-Heum Int J Environ Res Public Health Article Background: Neoadjuvant chemoradiotherapy (nCRT) prior to surgery is considered standard therapy for locally advanced rectal cancer. Unfortunately, most patients with rectal cancer are resistant to radiotherapy. This might be a genetic cause. The role of certain rectal cancer-causing genes has not been completely elucidated. This study aims to investigate the genes responsible for locally advanced rectal cancer patients not reacting to radiotherapy. Methods: Whole exome sequencing of the DNA samples was performed on the samples. Bioinformatic analysis on the subjects was established. Individual genetic information was screened to identify differently expressed genes that more frequently appeared in non-complete response (NCR) compared to complete response (CR) patients after nCRT. All variations were verified by Sanger sequencing. Results: Genotyping information and pathway analyses of the samples indicated genes such as FLCN, CALML5, and ANTXR1 to be commonly mutated in CR group, whereas genes such as GALNTL14, CNKSR1, ACD, and CUL3 were more commonly mutated in the NCR group. Chi-square test revealed some significant variants (<0.05) such as rs3744124 (FLCN), rs28365986 (ANTXR1), rs10904516 (CALML5), rs3738952 (CUL3), rs13394 and rs2293013 (PIH1D1), rs2274531 (GPA33), rs4963048 (BRSK2), rs17883366 (IL3RA), rs2297575 (PSMD5), rs2288101 (GALNT14), and rs11954652 (DCTN4). Conclusion: Identifying an array of genes that separate NCRs from CRs would lead to finding genetic biomarkers for early detection of rectal cancer patients that are resistant to nCRT. A further investigation to validate the significance of genetic biomarkers to segregate NCRs from CRs should be performed with a larger CRC dataset. Protein expression levels, as well as transcriptomic analysis, would also help us understand the mechanism of how these genes could play a role in preventing radiation therapy to patients. This would be essential to prevent redundant radiation therapy. MDPI 2022-03-28 /pmc/articles/PMC8997875/ /pubmed/35409691 http://dx.doi.org/10.3390/ijerph19074008 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bagaria, Jaya
Kim, Kyung-Ok
Bagyinszky, Eva
An, Seong Soo A.
Baek, Jeong-Heum
Discriminating Potential Genetic Markers for Complete Response and Non-Complete Response Patients to Neoadjuvant Chemotherapy with Locally Advanced Rectal Cancer
title Discriminating Potential Genetic Markers for Complete Response and Non-Complete Response Patients to Neoadjuvant Chemotherapy with Locally Advanced Rectal Cancer
title_full Discriminating Potential Genetic Markers for Complete Response and Non-Complete Response Patients to Neoadjuvant Chemotherapy with Locally Advanced Rectal Cancer
title_fullStr Discriminating Potential Genetic Markers for Complete Response and Non-Complete Response Patients to Neoadjuvant Chemotherapy with Locally Advanced Rectal Cancer
title_full_unstemmed Discriminating Potential Genetic Markers for Complete Response and Non-Complete Response Patients to Neoadjuvant Chemotherapy with Locally Advanced Rectal Cancer
title_short Discriminating Potential Genetic Markers for Complete Response and Non-Complete Response Patients to Neoadjuvant Chemotherapy with Locally Advanced Rectal Cancer
title_sort discriminating potential genetic markers for complete response and non-complete response patients to neoadjuvant chemotherapy with locally advanced rectal cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8997875/
https://www.ncbi.nlm.nih.gov/pubmed/35409691
http://dx.doi.org/10.3390/ijerph19074008
work_keys_str_mv AT bagariajaya discriminatingpotentialgeneticmarkersforcompleteresponseandnoncompleteresponsepatientstoneoadjuvantchemotherapywithlocallyadvancedrectalcancer
AT kimkyungok discriminatingpotentialgeneticmarkersforcompleteresponseandnoncompleteresponsepatientstoneoadjuvantchemotherapywithlocallyadvancedrectalcancer
AT bagyinszkyeva discriminatingpotentialgeneticmarkersforcompleteresponseandnoncompleteresponsepatientstoneoadjuvantchemotherapywithlocallyadvancedrectalcancer
AT anseongsooa discriminatingpotentialgeneticmarkersforcompleteresponseandnoncompleteresponsepatientstoneoadjuvantchemotherapywithlocallyadvancedrectalcancer
AT baekjeongheum discriminatingpotentialgeneticmarkersforcompleteresponseandnoncompleteresponsepatientstoneoadjuvantchemotherapywithlocallyadvancedrectalcancer